New Delhi: During the second wave of this pandemic, AYUSH-64 and Kabasura Kudineer were reassigned for COVID 19 after strong scientific studies found them useful in asymptomatic, mild and moderate COVID-19 infection as a autonomous and / or in addition to the standard care according to studies carried out by the Ayush Ministry in collaboration with the Ministry of Health and Family Welfare, the Ministry of Science and Technology (CSIR and DBT), the Department of Science and Technology and reputable scientific organizations and hospitals. However, the government. of India has published the “National Ayurveda and Yoga Based Clinical Management Protocol for the Management of COVID-19”.
State Licensing Authorities / UTs / Drug Controllers have been advised to allow licensed manufacturers of AYUSH-64 under their jurisdiction to include a new indication of AYUSH-64 for reassignment as a. intervention for the management of asymptomatic, mild to moderate COVID-19 in addition to existing indications. In addition, state licensing authorities / UTs have been urged to expedite the process of authorizing / approving the manufacturing application for AYUSH-64.
The ministry has taken the following steps to reduce / exterminate the effects of COVID-19: –
I. The Ayush Ministry formed an Interdisciplinary AYUSH Research and Development Working Group chaired by Professor Bhushan Patwardhan and composed of scientists from the Indian Council for Medical Research (ICMR), Department of Biotechnology (DBT), of the Council for Scientific and Industrial Research (CSIR), All India Institute of Medical Sciences (AIIMS) and Ayush Institutions. The AYUSH Interdisciplinary Research and Development Working Group formulated and designed clinical research protocols for prophylactic studies and complementary interventions in COVID-19 positive cases through extensive review and expert advisory process of great reputation of different organizations across the country to study four different interventions viz. Ashwagandha, Yashtimadhu, Guduchi + Pippali and a poly herbal formulation (AYUSH-64).
ii. Ayush’s ministry has also launched interdisciplinary studies involving AYUSH interventions for COVID-19 based on the task force’s recommendations. Within the framework of various national research organizations and institutes under the ministry of Ayush, 126 research studies in 152 centers nationwide have been initiated on AYUSH interventions.
iii. The Ayush Department has formed an Interdisciplinary Technical Review Committee (ITRC) for COVID-19 to review patented and proprietary ASU & H drug applications / claims / ASU & H conventional drugs forwarded by licensing authorities to State / individuals.
This information was given by Ayush Minister of State Shri Mahendrabhai Munjapara in a written response to Rajya Sabha today.